Alkermes, Inc. (Alkermes) is an integrated biotechnology company. The Company has developed, manufactured and commercialized VIVITROL for alcohol dependence and manufactured RISPERDAL CONSTA for schizophrenia and bipolar disorder. Its pipeline includes injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. It has research facilities in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is the long-acting, atypical antipsychotic to be approved by the United States Food and Drug Administration (FDA). RISPERDAL CONSTA is approved for the treatment of schizophrenia in approximately 85 countries and marketed in approximately 60 countries. In the United States, RISPERDAL CONSTA is also approved for the treatment of bipolar I disorder.